Recent News:
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
Recent News:

Developing Allogeneic, Off-the-Shelf Virus-Specific T Cell (VST) Therapy Candidates Targeting Twelve Devastating Viruses

Learn how our allogeneic, off-the-shelf VSTs are designed to treat or prevent devastating viral infections and diseases in patients with T cell deficiencies who have limited or no treatment options.
Down Arrow

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.
VIEW

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.
learn

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.
meet

Restoring Immunity

Our approach involves the restoration of viral immunity through the adoptive transfer of VSTs, which have been prospectively generated from healthy, eligible donors. These cells are immediately available for patients at risk from the life-threatening consequences of viral diseases due to T cell deficiencies, including transplant recipients, immunocompromised cancer patients, the elderly, and the very young.

Virus-Specific T Cells Play a Central Role in Response to Viral Infection

Adaptive Cellular Immune Response in a Healthy Individual: Virus-specific T cell responses are vital components in cellular immunity against devastating viruses.

Viral Infection Activates and Expands Endogenous Helper (CD4+) and Cytotoxic (CD8+) T Cells

Expanded T cells Migrate to Site of Infection and Bind to Virus-infected cells

Selective Killing of Virus-infected Cells

1
2
3
AlloVir’s Proprietary, Highly Efficient Platform Provides Key Advantages. Ready to learn more?

Cambridge

139 Main Street
Suite 500
Cambridge, MA 02142

Houston

2925 Richmond Ave
Suite 1200
Houston, TX 77098

Company

About UsContact Us617-433-2605
ContactCareers
AlloVir ©2020 All rights reserved

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno

You are now leaving AlloVir’s website.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
yesno